The M&A landscape is evolving as a new tier of large, but not Big Pharma-sized, biotechs are now executing their own billion-dollar acquisitions. Companies like Neurocrine, BioMarin, and Genmab are creating a new class of strategic buyers, diversifying exit opportunities for smaller biotech firms.
According to Jato's founder, global Limited Partners (LPs) from the US, Asia, and Brazil are showing new, strong interest in European biotech investments, a significant shift from past sentiment. This change is partly driven by geopolitics, potentially creating a valuation arbitrage opportunity as European biotechs are often initially valued lower than US peers.
Industry experts criticize the FDA's requirement for extensive stability testing before Phase 1 trials as 'putting the cart before the horse.' This demand imposes significant time and cost on a product that has not yet passed the fundamental go/no-go human safety test, a risk that sponsors argue they should manage themselves.
The FDA's proposal to use non-animal models for first-in-human trials is a long-term scientific shift. However, competitors like Australia and China achieve faster trial starts now by simply streamlining existing regulatory processes, making them more attractive for biotech companies in the short-term.
The FDA retreated from its initial plan to impose a $10M penalty on companies conducting initial trials abroad. The new proposal, a modest $2M fee reduction for domestic trials, is considered too small to change corporate strategy, effectively making the policy a symbolic gesture rather than a meaningful incentive.
Blackstone Life Sciences provides large-scale, risk-sharing capital for late-stage clinical programs. This model allows biopharmas, including large companies like Merck, to fund costly trials for blockbuster-potential assets without tapping public markets or straining internal R&D budgets, thus accelerating development.